Video

What the impact of 44-week aflibercept data may mean in a real-world setting

Author(s):

Sheryl Stevenson,Emily Kaiser Maharjan
Conferences|ASRS Preview

David Brown, MD, highlights his ASRS poster that includes 44-week data for a four-times-higher dose of aflibercept in a real-world setting.

Related Videos
Bonnie An Henderson, MD, and EnVision Summit 2025 preview
Vikas Chopra, MD, at AAO 2024: The role of MIGS in earlier intervention and safer techniques
Related Content
USC researchers receive $6 million CIRM grant to advance novel dry AMD therapy
November 21st 2024

USC researchers receive $6 million CIRM grant to advance novel dry AMD therapy

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

Innovation and the clinician-scientist
November 20th 2024

Innovation and the clinician-scientist

Robert Chang, MD, discusses the impact of large language models on glaucoma care and AI in ophthalmology
November 5th 2024

Innovation Series: Putting the buzz of large language models in ophthalmology into perspective with Robert T. Chang, MD

Emmecell announces topline results from Phase 1 extension study of EO2002 for corneal edema
November 18th 2024

Emmecell announces topline results from Phase 1 extension study of EO2002 for corneal edema

Teprotumumab: TED treatment shows benefits for patients
November 18th 2024

Teprotumumab: TED treatment shows benefits for patients

© 2024 MJH Life Sciences

All rights reserved.